InterVenn BioSciences

InterVenn BioSciences Utilizes Proprietary Glycoproteomic Biomarker Interrogation Platform with AI and Mass Spectrometry for Next-Generation Precision Medicine. The Company is Focused on Finding New Solutions for Ovarian Cancer, Pancreatic Cancer, Liver Cancer, Prostate Cancer, and Kidney Cancer, Along with Applications of the Vista Solution Suite for Treatment and Monitoring, Immunoassays, Patient Stratification, and Disease Progression.